0001615774-15-001372.txt : 20150604
0001615774-15-001372.hdr.sgml : 20150604
20150604172438
ACCESSION NUMBER: 0001615774-15-001372
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20150602
FILED AS OF DATE: 20150604
DATE AS OF CHANGE: 20150604
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SECOND SIGHT MEDICAL PRODUCTS INC
CENTRAL INDEX KEY: 0001266806
STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
IRS NUMBER: 000000000
STATE OF INCORPORATION: CA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 12744 SAN FERNANDO ROAD, BLDG. 3
CITY: SYLMAR
STATE: CA
ZIP: 91342
BUSINESS PHONE: 818-833-5000
MAIL ADDRESS:
STREET 1: 12744 SAN FERNANDO ROAD, BLDG. 3
CITY: SYLMAR
STATE: CA
ZIP: 91342
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Greenberg Robert J.
CENTRAL INDEX KEY: 0001625594
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36747
FILM NUMBER: 15913805
MAIL ADDRESS:
STREET 1: 12744 SAN FERNANDO ROAD, BLDG. 3
CITY: SYLMAR
STATE: CA
ZIP: 91342
4
1
s101270_form4.xml
4
X0306
4
2015-06-02
0
0001266806
SECOND SIGHT MEDICAL PRODUCTS INC
EYES
0001625594
Greenberg Robert J.
12744 SAN FERNANDO ROAD, BLDG. 3
SYLMAR
CA
91342
1
1
0
0
CHIEF EXECUTIVE OFFICER
COMMON STOCK
2015-06-02
4
M
0
78153
4.75
A
301187
D
COMMON STOCK
2015-06-02
4
F
0
26586
13.96
D
275231
D
COMMON STOCK
2015-06-02
4
S
0
78153
13.96
D
197078
D
COMMON STOCK
2015-06-03
4
M
0
71847
4.75
A
268925
D
COMMON STOCK
2015-06-03
4
F
0
24167
14.12
D
244758
D
COMMON STOCK
2015-06-03
4
S
0
71847
14.12
D
172911
D
Option
4.75
2015-06-02
4
M
0
78153
0
A
2015-09-01
Common Stock
78153
71847
D
Option
4.75
2015-06-03
4
M
0
71847
0
A
2015-09-01
Common Stock
71847
0
D
Option
4.25
2017-01-01
Common Stock
125000
125000
D
Option
4.75
2016-01-01
Common Stock
17969
17969
D
Option
5.00
2016-05-01
Common Stock
8223
8223
D
Option
5.00
2017-01-01
Common Stock
30625
30625
D
Option
5.00
2018-02-01
Common Stock
23750
30625
D
Option
5.00
2018-11-01
Common Stock
150000
150000
D
Option
5.00
2019-02-01
Common Stock
33750
33750
D
Option
5.00
2020-02-01
Common Stock
53125
53125
D
Option
5.00
2020-02-01
Common Stock
50625
50625
D
Option
5.00
2021-03-01
Common Stock
41563
41563
D
Option
5.00
2022-03-01
Common Stock
29063
29063
D
Option
5.00
2024-04-01
Common Stock
11719
11719
D
Dr. Greenberg exercised 78,153 vested options reported as Option(C) on Form 3 filed with the SEC on November 18, 2014.
Dr. Greenberg tendered 26,586 shares of common stock to the Company in accordance with Rule 16b-3.
The fair market value on the day of the exercise.
The price reported in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $13.56 to $14.35, inclusive. The broker remitted $277,224 to the Company to cover withholding obligations. The reporting person undertakes to provide to the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. These transactions were effected pursuant to planned sales under lock-up agreement entered into at the time of EYES IPO in November 2014, as approved by Board of EYES and the IPO underwriter and as further disclosed in the Company's final prospectus dated November 20, 2014.
Dr. Greenberg exercised 71,847 vested options reported as Option(C) on Form 3 filed with the SEC on November 18, 2014.
Dr. Greenberg tendered 24,167 shares of common stock to the Company in accordance with Rule 16b-3.
The price reported in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $13.50 to $14.64, inclusive. The broker remitted $351,333 to the Company to cover withholding obligations. The reporting person undertakes to provide to the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. These transactions were effected pursuant to planned sales under lock-up agreement entered into at the time of EYES IPO in November 2014, as approved by Board of EYES and the IPO underwriter and as further disclosed in the Company's final prospectus dated November 20, 2014.
These are vested employee options currently exercisable.
Excludes unvested employee options covering 490,752 shares, not exercisable for over 60 days from this date. Sales were automatically effected pursuant to 10b5-1 trading plan and trades reported on this Form 4 constitute the final trades pursuant to this 10b5-1 plan adopted by the reporting person.
/s/ Robert J. Greenberg
2015-06-04